Kenneth B Tucker

Address:

1669 Gemini Dr, Sykesville, MD 21784

Phone:

(410)5520843

VIN:

1GCDT13E278190272

Make:

CHEVROLET

Model:

COLORADO

Year:

2007

US Patent:

6514965, Feb 4, 2003

Filed:

Nov 7, 2000

Appl. No.:

09/706863

Inventors:

Alenka Tomazic - Gaithersburg MD
Liren Huang - Rockville MD
Kenneth D. Tucker - Frederick MD

Assignee:

Antex Pharma Inc. - Gaithersburg MD

International Classification:

C07D48700

US Classification:

51421207, 540523

Abstract:

This invention relates to substituted 1-benzazepines and derivatives thereof useful as antibacterial agents, to compositions, including pharmaceutical compositions, comprising such compounds, to processes for making these compounds and to methods of using these compounds for killing bacteria or inhibiting bacterial growth.

US Patent:

6541616, Apr 1, 2003

Filed:

Oct 1, 1998

Appl. No.:

09/164714

Inventors:

Kenneth Tucker - Germantown MD
Ulrich F. Tillmann - Olney MD

Assignee:

Antex Biologics Inc. - Gaithersburg MD

International Classification:

C12N 1511

US Classification:

536 231, 536 2332, 4353201

Abstract:

The invention discloses the outer membrane protein polypeptide and polypeptides derived therefrom (collectively âOMP21â), nucleotide sequences encoding said OMP21, and antibodies that specifically bind OMP21. Also disclosed are pharmaceutical compositions including prophylactic or therapeutic compositions, which may be immunogenic compositions including vaccines, comprising OMP21, antibodies thereto or nucleotides encoding same. The invention additionally discloses methods of inducing an immune response to and OMP21 in an animal, preferably a human, methods of treating and methods of diagnosing Moraxella infections in an animal, preferably a human, and kits therefor.

US Patent:

7341727, Mar 11, 2008

Filed:

May 3, 1996

Appl. No.:

08/642712

Inventors:

Kenneth Tucker - Germantown MD, US
Laura Plosila - Cary NC, US

Assignee:

Emergent Product Development Gaithersburg Inc. - Gaithersburg MD

International Classification:

A61K 39/00

US Classification:

4241901, 530324, 530328

Abstract:

The invention discloses the outer membrane protein-106 (OMP106) polypeptide, polypeptides derived therefrom (OMP106-derived polypeptides), nucleotide sequences encoding said polypeptides, and antibodies that specifically bind the OMP106 polypeptide and/or OMP106-derived polypeptides. Also disclosed are immunogenic, prophylactic or therapeutic compositions, including vaccines, comprising OMP106 polypeptide and/or OMP106-derived polypeptides. The invention additionally discloses methods of inducing immune responses to and OMP106 polypeptides and OMP106-derived polypeptides in animals.

US Patent:

20080145916, Jun 19, 2008

Filed:

Oct 26, 2007

Appl. No.:

11/925586

Inventors:

Kenneth Tucker - Germantown MD, US
Laura Plosila - Cary NC, US

International Classification:

C12N 1/20
C07K 16/12

US Classification:

4352521, 5303879

Abstract:

The invention discloses the outer membrane protein-106 (OMP106) polypeptide, polypeptides derived therefrom (OMP106-derived polypeptides), nucleotide sequences encoding said polypeptides, and antibodies that specifically bind the OMP106 polypeptide and/or OMP106-derived polypeptides. Also disclosed are immunogenic, prophylactic or therapeutic compositions, including vaccines, comprising OMP106 polypeptide and/or OMP106-derived polypeptides. The invention additionally discloses methods of inducing immune responses to and OMP106 polypeptides and OMP106-derived polypeptides in animals.

US Patent:

62149814, Apr 10, 2001

Filed:

Nov 12, 1997

Appl. No.:

8/968685

Inventors:

Kenneth Tucker - Frederick MD
Laura Plosila - Cary NC
Ulrich F. Tillman - Olney MD

Assignee:

Antex Biologics Inc. - Gaithersburg MD

International Classification:

C07H 2102

US Classification:

536 231

Abstract:

The invention discloses the Moraxella catarrhalis outer membrane protein-106 (OMP106) polypeptide, polypeptides derived therefrom (OMP106-derived polypeptides), nucleotide sequences encoding said polypeptides, and antibodies that specifically bind the OMP106 polypeptide and/or OMP106-derived polypeptides. Also disclosed are immunogenic, prophylactic or therapeutic compositions, including vaccines, comprising OMP106 polypeptide and/or OMP106-derived polypeptides. The invention additionally discloses methods of inducing immune responses to M. catarrhalis and M. catarrhalis OMP106 polypeptides and OMP106-derived polypeptides in animals.

US Patent:

20090053292, Feb 26, 2009

Filed:

Dec 21, 2007

Appl. No.:

12/004502

Inventors:

Kenneth Tucker - Frederick MD, US
Ulrich F. Tillmann - Mount Laurel NJ, US

International Classification:

A61K 9/127
C07K 14/195
C12N 1/20
G01N 33/543
C12Q 1/68
C07K 16/12
A61K 39/02

US Classification:

424450, 530350, 530324, 4241901, 4352521, 5303895, 435 732, 435 6

Abstract:

The invention discloses the outer membrane protein polypeptide and polypeptides derived therefrom (collectively “OMP21”), nucleotide sequences encoding said OMP21, and antibodies that specifically bind OMP21. Also disclosed are pharmaceutical compositions including prophylactic or therapeutic compositions, which may be immunogenic compositions including vaccines, comprising OMP21, antibodies thereto or nucleotides encoding same. The invention additionally discloses methods of inducing an immune response to and OMP21 in an animal, preferably a human, methods of treating and methods of diagnosing infections in an animal, preferably a human, and kits therefor.

US Patent:

20030235592, Dec 25, 2003

Filed:

Feb 19, 2003

Appl. No.:

10/369299

Inventors:

Kenneth Tucker - Germantown MD, US
Ulrich Tillmann - Olney MD, US

Assignee:

Antex Biologics, Inc.

International Classification:

A61K039/02
C07H021/04
C12P021/02
C12N001/21
C07K014/195

US Classification:

424/190100, 536/023700, 435/069300, 435/320100, 435/252300, 530/350000

Abstract:

The invention discloses the outer membrane protein polypeptide and polypeptides derived therefrom (collectively “OMP21”), nucleotide sequences encoding said OMP21, and antibodies that specifically bind OMP21. Also disclosed are pharmaceutical compositions including prophylactic or therapeutic compositions, which may be immunogenic compositions including vaccines, comprising OMP21, antibodies thereto or nucleotides encoding same. The invention additionally discloses methods of inducing an immune response to and OMP21 in an animal, preferably a human, methods of treating and methods of diagnosing Moraxella infections in an animal, preferably a human, and kits therefor.

US Patent:

20070087019, Apr 19, 2007

Filed:

Oct 16, 2006

Appl. No.:

11/580854

Inventors:

Kenneth Tucker - Frederick MD, US
Laura Plosila - Cary NC, US
Ulrich Tillman - Mount Laurel MD, US

International Classification:

A61K 39/02
C07H 21/04
C12N 1/21
C07K 14/195
C12N 15/74

US Classification:

424251100, 435069300, 435252300, 435471000, 530350000, 536023700

Abstract:

The invention discloses the outer membrane protein-106 (OMP106) polypeptide, polypeptides derived therefrom (OMP106-derived polypeptides), nucleotide sequences encoding OMP106 polypeptides, and antibodies that specifically bind the OMP106 polypeptide and/or OMP106-derived polypeptides. Also disclosed are immunogenic, prophylactic or therapeutic compositions, including vaccines, comprising OMP106 polypeptide and/or OMP106-derived polypeptides. The invention additionally discloses methods of inducing immune responses to and OMP106 polypeptides and OMP106-derived polypeptides in animals.